Biallelic RIPK1 Mutations in Humans Cause Severe Immunodeficiency, Arthritis, and Intestinal Inflammation

Delphine Cuchet-Lourenco,Davide Eletto,Changxin Wu,Vincent Plagnol,Olivier Papapietro,James Curtis,Lourdes Ceron-Gutierrez,Chris M. Bacon,Scott Hackett,Badr Alsaleem,Mailis Maes,Miguel Gaspar,Ali Alisaac,Emma Goss,Eman AlIdrissi,Daniela Siegmund,Harald Wajant,Dinakantha Kumararatne,Mofareh S. AlZahrani,Peter D. Arkwright,Mario Abinun,Rainer Doffinger,Sergey Nejentsev
DOI: https://doi.org/10.1126/science.aar2641
IF: 56.9
2018-01-01
Science
Abstract:RIPK1 (receptor-interacting serine/threonine kinase 1) is a master regulator of signaling pathways leading to inflammation and cell death and is of medical interest as a drug target. We report four patients from three unrelated families with complete RIPK1 deficiency caused by rare homozygous mutations. The patients suffered from recurrent infections, early-onset inflammatory bowel disease, and progressive polyarthritis. They had immunodeficiency with lymphopenia and altered production of various cytokines revealed by whole-blood assays. In vitro, RIPK1-deficient cells showed impaired mitogen-activated protein kinase activation and cytokine secretion and were prone to necroptosis. Hematopoietic stem cell transplantation reversed cytokine production defects and resolved clinical symptoms in one patient. Thus, RIPK1 plays a critical role in the human immune system.
What problem does this paper attempt to address?